Boston Scientific highlights clinical trial representation: stock pre-market at EUR 39.31
Published on 10/16/2026 at 08:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDates and trading details
- Boston Scientific’s newsroom published a clinical-trial representation article on October 14, 2026.
- Boston Scientific stock trades pre-market at EUR 39.31 at 8:11 a.m. CEST on October 16, 2026, at Lang & Schwarz.
- The Lang & Schwarz bid was EUR 39.13 and the ask was EUR 39.50 on October 16, 2026.
Boston Scientific’s newsroom highlighted the company’s work on clinical trial representation in an article published October 14, 2026. At 8:11 a.m. CEST on October 16, Boston Scientific stock was at EUR 39.31 pre-market at Lang & Schwarz.
Pre-market trading
The Lang & Schwarz bid was EUR 39.13 and the ask was EUR 39.50 at the quoted time. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Boston Scientific stock.
What matters today: Boston Scientific’s newsroom article on clinical trial representation was dated October 14, 2026. The company’s next results date is listed as October 28, 2026. The Lang & Schwarz quote showed a bid of EUR 39.13 and an ask of EUR 39.50 on October 16, 2026.
Boston Scientific’s official newsroom also lists the company’s appointment of Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027. The release was published October 7, 2026. Boston Scientific published both items in its newsroom.
Market context: Market report S&P 500.
